Novo Nordisk (NVO) is up 3.9% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is a fresh boost to Wegovy demand after Medicare’s GLP-1 Bridge began on July 1, opening a new access route for eligible seniors at a fixed monthly copay. Investors also appear to be leaning on Novo Nordisk’s recent signs of commercial traction in obesity care, especially the rapid uptake of the Wegovy pill.
Details:
CMS started the Medicare GLP-1 Bridge on July 1, 2026, giving eligible Medicare Part D beneficiaries access to certain GLP-1 medicines through December 31, 2027.The program uses a $50 copay for eligible patients, which lowers the out-of-pocket barrier and could broaden access to obesity treatment for older adults.Novo Nordisk said Wegovy injection and pill are available through that program nationwide, creating a new near-term channel for prescriptions and refill demand.Novo Nordisk also said in June that Wegovy pill prescriptions had surpassed 3 million since launch, reinforcing the view that its obesity franchise still has meaningful volume momentum.Sources:
CMS, Novo Nordisk, Novo Nordisk
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
EARLY ACCESS
Receive NVO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$NVO Hedge Fund Activity
We have seen 516 institutional investors add shares of $NVO stock to their portfolio, and 672 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 19,333,750 shares (+inf%) to their portfolio in Q1 2026, for an estimated $693,211,606
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 9,884,077 shares (+808.8%) to their portfolio in Q1 2026, for an estimated $354,393,580
- FMR LLC removed 8,664,705 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $310,672,997
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 7,827,491 shares (+inf%) to their portfolio in Q1 2026, for an estimated $280,654,689
- TWO SIGMA INVESTMENTS, LP added 5,943,310 shares (+1731.8%) to their portfolio in Q1 2026, for an estimated $213,097,380
- GOLDMAN SACHS GROUP INC removed 5,865,741 shares (-53.4%) from their portfolio in Q1 2026, for an estimated $210,316,143
- BOSTON PARTNERS removed 5,231,804 shares (-97.3%) from their portfolio in Q1 2026, for an estimated $187,586,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NVO Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Novo Nordisk Rises as Medicare Access Expansion and Wegovy Momentum Support Shares
Novo Nordisk (NVO) is up 3.9% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is a fresh boost to Wegovy demand after Medicare’s GLP-1 Bridge began on July 1, opening a new access route for eligible seniors at a fixed monthly copay. Investors also appear to be leaning on Novo Nordisk’s recent signs of commercial traction in obesity care, especially the rapid uptake of the Wegovy pill.
Details:
Sources:
CMS, Novo Nordisk, Novo Nordisk
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$NVO Hedge Fund Activity
We have seen 516 institutional investors add shares of $NVO stock to their portfolio, and 672 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NVO Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $57.25.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »